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@t&wsTheaimoftkisstodywastoinvesttgatetkebasal 
release ofnitric oxble al spa&k sites ia patients with varisnt angina. 
Ruckgmund. We previoosly reported that endotheliom- 
depeadent dtlator responses to acetylchdiae, substance P and 
bradykiaia are preserved at tbe site of coronary artery spasm. 
However, it is sot known wbetber tbe basal release of 
eadotkelium- derivxd nitric oxide is alten at tbe spastic site. 
MethoBs. The effects of iatracoronary NG-monometbyh- 
aq$niw (bNMIb¶A, an Inhibitor of nitric oxide synthesis) at 
eumubdive doses of 50,100 and 24Xl mol on basal coronary 
artery tone were investigated in eight patients witb variant angina 
aad aormal coronary angiugmms and in eight control sabjects. 
The lumen diameters of large epkxrdial comnary arteries were 
assessed by qaantitative coronary arteriograpby. 
The vascular endothelium plays an important role in the 
maintenance of vascular tone by releasing various dilating 
and constricting substances (l-3). Recently, an important 
endothelium-derived relaxing factor has been identified as 
nitric oxide or a related compound (4J). L-Arginine analogues 
such as p-monomethyl+arginine (L-NMMA) inhibit the 
qnthesis of nitric oxide at rest and under conditions of 
acetylcholine stimulation in animals and humans (3). Quyyumi 
et al. (6) have investigated the effects of the intracoronary 
infusion of L-NMMA in patients with normal coronary arte- 
riograms and have suggested that nitric oxide contributes to 
the resting coronary artery tone in the human coronary 
circulation. 
The pathogenesis of coronary artery spasm is related closely 
to the process of atherosclerosis (7,8). The angiographic 
location of coronary artery spasm has been linked to histologic 
evidence of intimal thickening in swine (9-11) and human (12) 
Results. Coronary spasm was provoked by the intracomoary 
administratioa of acetylcholii in all patients with variant angina. 
L.-NM&I did not alter the arterial pressure aad heart rate bat 
slgnllntly flecreasd the coronary artery diimeter at spastic 
aad nonspastic sites. Con&i&e responses to L-NMMA were 
sigaificantly greater (p < 0.01) at tbe spastic site (constrietioa by 
2&l cund, 22 c 7%, mean 2 SD) tbaa at the nonspastic site (10 2 
7%). Constrictive responses to LAMMA at tbe aonspastic site in 
patients with variant aagiaa were comparable to tbose in tbe 
control sabjects. 
Conch. These findings support tbe hypotkesis that tbe 
basal release of nitric oxide may sot be decreased at the spastic 
site in patients with variant angina. 
(JAm Cdl CatSol 19%;27:1444-9) 
models of coronary spasm. Therefore, it is plausible that even 
in the absence of angiographically detectable atherosclerosis, 
there might be some degree of early atherosclerotic changes at 
the sites of coronary artery spasm. Although atherosclerosis 
may impair endotheliumdependent dilation to acetylcholine 
(l-3,13-15), endothelium-related vasodilator responses to sub- 
stance P and calcitonin gene-related peptide are preserved at 
atherosclerotic segments in humans (16,17). We (18-20) have 
demonstrated that endothelium-dependent vasodilator re- 
sponses to acetylcholine, substance P and bradykinin are 
preserved at the spastic site in patients with variant angina. 
However, it is unknown whether the basal production or 
release of nitric oxide is altered at the spastic site in such 
patients. Indeed, basal coronary artery tone is elevated at the 
spastic site in a subgroup of patients with variant angina 
(19,21-U). The latter finding may imply that the decreased 
production of some dilator substances, including nitric oxide, 
may contribute to the elevated basal tone. Therefore, we designed 
tbii study la investigate whether the basal release of nitric oxide is 
altered at the spastic site in patients with variant angina. 
Methods 
w cnitort. Eight patients with variant angina and nor- 
mal coronary artexiograms (mean age 68 + 8; four men, Four 
women) were studied (Table 1). AU patients with variant 
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Tattle 1. Patient Characteristics 
onrgs 
PI AK cbolestcd Bcfae the static Control 
NO. fyT)/Gendcr Level (mgldl) Smoking HT DIM study Site* Site” 
angina had a typical history of angina1 pain at rest. In these that from the object to the image intensitier were kept constant 
patients, coronary artery spasm (lumen reduction ~75%) during the study. An end-diastolic arteriogram frame was 
associated with ischemic ST segment elevation (n = 5) or selected, and the lumen diameter of the large epicardial 
depression (n = 3) was angiographiily provoked in one or coronary artery was determined using a valiited densitomet- 
more segments of the left coronary artery by the intracoronary ric analysii system as previously descnr (l&19). Readily 
infusion of acetyjcholine (100 &min into the left coronary identifiable branch points were determined as reference mark- 
artery) as previously described (16,17). Fiie of eight patients ers to allow assessment of serial changes in the diameter at the 
complained of anginal chest pain during the provoked spasm. same arterial site. Changes in the diameter in response to 
Patients in whom diffuse spasm was provoked or the spasm drugs were expressed as percent changes from the baseline 
occurred in peripheral segments were excluded. value. 
Eight patients with atypical chest pain and normal coronary 
arteriograms (mean age 57 t 9; five men, three women) in 
whom neither coronary artery spasm, chest pain nor ischemic 
ST segment changes were provoked by acetylcholine were 
studied as control subjects. Patients with a history of myocar- 
dial infarction, valvular heart disease or left ventricular dys- 
function were excluded. 
Risk factors for coronary atherosclerosis examined in 
this study included hypercholesterolemia (total cholesterol 
>220 mg/dl), essential hypertension (systolic blood pressure 
>I40 mm Hg and/or diastolic blood pressure >90 mm Hg), 
smoking, age >60 years. family history of ischemic heart 
disease and diabetes mellitus (fasting blood glucose 2140 mg/dl 
or a positive ghtccsc tolerance test). Of eight patients with 
variant angina, two were free of risk factors, one had one risk 
factor, three had two risk factors and two had four risk factors 
(Table 1). Of eight control subjects, three were free of risk 
factors, two had one risk factor, two had two risk factors and 
one had four risk factors. Thus, there was no sign&zan’ 
ditTerence in the risk factor profiles between the two groups 
In patients with variant angina, we determined changes in 
the lumen diameter at 12 paired spastic and nonspastic sites 
(Table 1). The nonspastic site was defined as an adjacent 
segment proximal or distal to the spastic site or as a segment of 
another, nonspastic vessel with a baseline diameter similar to 
that at the spastic she. In control subjects we determined 
changes in the lumen diameter at segments of the left coronary 
artery with a baseihte diameter similar to that at the spastic site 
in patients with variant angina. 
QaantitatIve emmary zaaMhp@. Coronary arterio- 
grams were recorded and analyzed in a Minded manner using 
a Siemens angiographic system (&or and Hicor, Siemens- 
Asahi Inc.). An appropriate view that permitted clear +al- 
hationofthearterytobestudiedwassehxted.Theangleof 
theview,thed&ancefromtheX-rayfocustotheobjcctand 
M~tSDf~hhlOd!IWVebCIlyMd~ 
flow. Changes in ooronary blood flow in msponse to L-NNIMA 
were measured in five patients with variant angina and eight 
control subjects. A 6F Judkins catheter was placed at the left 
main coronary artery via a femoral approach. A Ox)lGrch 
(0.46 mm) Doppler-tipped, guide wire (FlowWii. CardiometT 
rics Inc.) was then advanced into the left coronary artery 
through the ludkins catheter. The tip was placed at the 
proximal segment of the spastic site in patients with variant 
angina and at the proximal segment of the left anterior 
dcsuding or left aimmukx coronary artery in the control 
subjects. Before and during the iufusion of L-WWA, the peak 
coronary blood Row velocity was monitored continuously using 
a fast Fourier transform-based spectmi analyzer (RowMap). 
Us&g arteriography, wc determined changes in the lumen 
~~areaatasegment3toSmmdistal~tBetipof 
the FkmWrc. Syskmic arterial pressure and heart rate were 
I 67iF 206 + - N =gb SqlI 
xgl *Fix 
xgl4 ugl? 
2 6fNF 207 D.3 sq&t ScRlJ 
3 59F 213 - k$w sq$J 
4 WM 159 + - segll szg7 
x-g12 w 
5 61M 148 + D F&4 543 
ug7t %a 
6 63A4 256 + D,N cegllf rg13 
7 Mb4 l&3 4. + - ress segll 
8 73/F 234 + + - D scget =g7 
‘Location of spasm site as defined by the American Heart Awciation. tCoronary blood %m was measured at the 
proximal segment (scg) of the spauic site before and after intracomnary NC-maomethyl-L-qjnine. D = diltiazem: 
DM=diabetsmellitls;F=female,HT=anerialhypertension;M=mak;N=nitrate:Pt=patiroSi;yes;-=w. 
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Table 2. Effects of L-NMMA on Mean Arterial Pressure, Heart Rate, Coronary Artery Diameters and 
Car, :aly BLod Flow 
L-NMMA (cumulative dose, pmol) 
Baseline 50 lot 203 
Patients with variant aqinina 
Mean arterial pressure (mm H8) 86% 14 W? I1 85 c I? 94+11 
Heart rate (beatsimin) 71 + 4 69 i 9 69 -’ 9 72 ? 9 
Comnarv artery diameter (mm) 
Control site 2.33 + 0.59 2.38 3 0.59 2.31 t 0.63 2.10 z 0.58’ 
Spastic site 2.25 f 0.44 2.32 ?r 0.45 2.20 i 0.44 1.75 t 0.36+ 
Gxonaty bled flow (mlimin) 4:z 19 41 ‘- 18 4oz IS 29 2 14% 
Control patients 
Mean arterial (mm Hg) pressure 83 + 8 8429 885 10 90?9 
Heart rate (beatsimin) 6626 64+9 67 + 9 66 + 9 
Coronary anery diameter (m:n) 2.32 i 0.86 .go 2 “!,!I 2.29 + 0.89 2.11 + 0.74’ 
Coronx~ bind flow (ml’min) 44221 45 2 20 37 2 14 35 f 13* -~ 
‘p < 0.05. tp < 0.01 wsus before N”-monomethyl-L-argininu (L-NMMA) by one-way analysis of variance f&wed 
by Bonferroni multiple comparison test. Data are mean 2 SD. 
continuously recorded. The steady-state signals were used for nary blood flow in patients with atypical chest pain and normal 
analysis. coronary angiograms (24). 
The mean peak blood flow velocity was determined, and the 
coronary blood flow (CBF) was calculated using the following 
formula: 
CRF (ml/mitt) = 0.5 X mean peak CBF velocity (cm/min) 
Second, acetylcholine was administered into the left coro- 
nary artery (100 &min), and then into the right coronary 
artery (50 &tin), to provoke coronary artery spasm. Coro- 
nary arteriography was performed 2 min after injection of 
acetylcholine. 
X cross-sectional area (cm’). 
Following the L-NMMA study, the FlowWire was with- 
drawn from the coronary artery and the Judkins catheter. 
St&y protoeok The study protocol was approved by the 
Institutional Review Committee on Human Research of the 
Research Institute of Angiocardiology, Kyushu University 
School of Medicine. Written informed consent was obtained 
from each patient. 
Cardiac catheterization was performed in the fasting state 
after oral premed&ion with 5 mg of diazepam. Antianginal 
or antihypertensive medications were discontinued at least 
24 h before the study (Table 1). After the baseline coronary 
arteriography had been completed, the following protocols 
were performed. 
Third, coronary arteriograms in multiple projections were 
recorded to assess the severity of atherosclerotic lesions 2 min 
after isosorbide dinitrate was administered into the left and 
right coronary arteries. When angina or ischemic ST segment 
elevation occurred in patients with variant angina following the 
administration of acetylcholine, isosorbide dinitrate was imme- 
diately administered into the spastic coronary artery, and 
coronary angiograms were recorded. The basal coronary artery 
tone was defined as the percent dilation in response to 
isosorbide dicitrate. 
Fii, the effects of NG-monomethyl-L-arginine (L-NMMA, 
CLINALFA Inc.) on coronary vasomotor responses were 
studied. After st @-state baseline hemodynamic parameters 
were recorded fcs 3, min and coronary arteriography was 
performed, L-NMMA at doses of 50, 59, and 100 wol 
(cumulative doses of 50,100, and 200 ~mol) were infused over 
1 min into the left coronary artexy through the Judkins 
catheter. Two minutes,after the beginning of each dose of 
L-NMMA, when hemodynamic parameters had stabilized, 
coronary arteriography was performed. We theo waited for 
1 min before &ninistering the next dose of L-NMMA. We 
confIrmed that these doses of L-NMMA completely inhl%ited 
acetylcholine (IO &min)-induced dilation of large epicardial 
coronary arteries and acetylcholine-induced increases in coro- 
Statistical analysis. Data are expresed as the mean ? SD 
in the text and the mean f SE in figures. Analysis of variance 
(ANOVA) for repeated measures followed by the Bonferroni 
multiple comparison test was used to compare serial changes in 
hemodynamic parameters in response to graded doses of 
L-NMMA. A Student t test was used to compare responses to 
isosorbide dinitrate. A probability level co.05 wzs considered 
statistical@ significant. 
Results 
Patient chara&rIstIcs, Table 1 shows clinical characteris- 
tics such as age, gender and serum cholesterol concentration as 
well as a history of arterial hypertension, smoking or antiangi- 
nal and antihypertensive drugs used before the study in 
patients with variant angina. 
EIkcts of L-NMMA Changes in the coronary artery diam- 
eter and other hemodynamie variables in response to intra- 
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Figure I. Line graphs of the effects of the 
intracoronav administration of I.-NMMA on 
the percent changes in the diameter of epi- 
cardial arteries (lumen reduction) in patients 
with variant angina (left) and control subjects 
(rtghl). Data are presented as the mean 2 SE. 
L-NMMA = N”-monomethyl-c.-ar~inine. *‘p < 
(I.01 versus the control site hy two-way analgsis 
of variance folltwcd hy Bonferroni multrplr 
comparison test. 
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coronary L-NMMA are shown in Table 2. fn patients with 
variant angina, the baseline lumen diameters at the spastic site 
did not significantly differ from those at the nonspastic site. 
L-NMMA did not significantly alter arterial pressure and heart 
rate hut significantly decreased the lumen diameters at both 
the spastic (p < 0.01) and nonspastic (p 4 U.05) sites. There 
was no significant difference in the responses of the lumen 
diameters to I.-NMMA between the two sites. However, the 
percent decrease in the lumen diameter evoked by L-NMMA 
was significantly greater (p < 0.01 by two-way ANOVA) at the 
spastic site than at the nonspastic site (Fig. 1). 
There was nc significant difference between patients with 
variant angina and control subjects concerning the baseline 
mean arterial pressure, heart rate, the lumen diameters of the 
large epicardial coronary arteries or their responses to L- 
NMMA (Table 2). The percent decrease. in the lumen diame- 
ter in the control subjects did not differ significantly from that 
at the nonspastic site in patients with variant angina (Fig. 1). 
L-NMMA significantly decreased coronary blood flow in 
five patients with variant angina and eight control subjects 
(Table ?). Them was no significant difference between patients 
with vxiant angina and the control subjects concerning the 
baseline coronary blood flow and its response to L-NMMA. 
Provocation of eoronaiy artev spasm. The intracoronary 
administration of acetytcholine after L-NMMA provoked cor- 
onary artery spasm at one or more segments in all eight 
patients with variant angina involving a total of I2 sites (Table 
1). The acetykholine-induced spasm occurred at 12 sites in 
eight patients. The percent decrease in lumen diameter in- 
duced by acetylcholine at the spastic sites (88 ? 10%) was 
significantly greater (p < 0.01) than that at the nonspastic sites 
(3f-l f II%). 
In control patients, intracoronary acetykholine aher L- 
NMMA caused neither anginal pain, coronary artery spasm, 
nor ischemic ST segment changes. The percent decrease in 
lumen diameter induced by acetykholine was 31 2 9% in these 
patients. 
Effects of isnsmbide dinitrate. The intracoronaty adminis- 
tration of 2 mg isosorbide dinitrate di3 not change the mean 
arterial pressure or heart rate but significantly increased the 
diameter of the coronary artery. The percent increase in the 
diameter at the spastic site (27 lr 115 ) was significantly 
greater (p = 0.01) than that at the nonspastic site (I7 + 75) 
in patients with variant angina. HJHT\ >r. the pcrceot increase 
in the diameter at the nonspastic site :G patients with variant 
angina did not differ from that in con’rols ( ~6 + 8G). 
Coronary arteriography after isosorbide dinitrate revealed 
that all patients and contra, subjects haJ angiographically 
normal coronary arteries. 
Discussion 
We previously reported that endothelium-dependent vase- 
dilating respomcs to acetykholine, substance P and bradykinin 
are preserved at spastic sites in patients with variant angina 
and normal coronary arteriograms (18-20). However, the 
basal release of nitric oxide at such spastic sites has not been 
investigated. The novel finding. in this study is that intramro- 
nary LNMMA caused greater constriction at spastic sites than 
nonspastic sites in patients with variant angina. 
Nitric oxide and basal coroaary artery tome. Nitric oxide is 
produced continuously by the endothelium in the absence of 
external stimulus in vivo. This is termed basal release. The 
shear stress caused by blood flow is the major stimulus for this 
phenomenon. t.-Arginine analogues such as &!MMA inhibit 
the release of nitric oxide from the endothelium at rest and 
under conditions of acetykholine stimulation (l-6). The intm- 
coronary infusion of L-NMMA causes coronary vasoconstric- 
tion in animals and humans in vivo (12.6). We have reccntiy 
reported that intracoronary infusion of L-NMMA (total 200 
smol) completely abolished acetykholine-i&ced dilation of 
large epicardial coronary arteries in patients with’ normal 
mronary arteriograms (24). In this study. the intracoronar) 
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infusion of L-NMMA (total 200 ~1) significantly decreased 
the basal lumen diameter of epicardial coronary arteries in 
patients with variant angina and control subjects. Thus, data 
from the present study and previous report (6) suggest that 
nitric oxide may contribute to the control of basal coronary 
artery tone at angiographically normal sites in humans. 
Bnsal release nf nitric oxide at site cd spnsm. We found in 
this study that the magnitude of constriction induced by the 
high dose (200 pmol) but not the low doses (50 and 100 pmol) 
of L-NMMA was greater at the spastic site than at the 
nonspastic site (Fig. 1). Quyyumi et al. (6) have demonstrated 
that t,NMMA-induced constriction of large epicardia1 coro- 
nary arteries in patients with normal coronary arteriograms is 
decreased by the presence of risk factors for coronary athero- 
sclerosis. However, it is unlikely that these altered responses of 
the spastic site to L-NhMA in patients with variant angina 
were caused by the presence of risk factors, because both the 
spastic and nouspastic sites were exposed to identical risk 
factors in each patient. Because there was no significant 
difference in the risk factor profiles between patients with 
variant angina and controls, our linding that constricting 
responses to L-NM of the nonspastic sites in patients with 
variant angina did not differ significantly from those in control 
subjects is consistent with the findings of Quyyumi et al. (6). 
Because the decreases in coronary blood flow in response to 
~-h&bL% were comparable between patients with variant 
angina and controls, it is unlikely that the altered responses to 
,NMMA at the spastic site resulted from changes in the 
coronary blood flow in response to L-NMMA L-NMMA did 
not significantly change the arterial pressure or heart rate. 
Therefore, it is likely that the coronary vasoconstriction in- 
duced by intracoronary L-NMMA resulted largely from the 
decreased release of nitric oxide from the endothelium. 
Although the nitric oxide-generating capacity was not in- 
vestigated directly in the present study, our finding of an altered 
vasoco~ respom to dMMA at the spastic site may 
suggest the folkming possiii First, the results of recent 
imwtigations have suggested that the expression of endothelial 
cmstitutive nitric oxide synthaw mRNA and uitric oxide protein 
produ&on are not impaired but rather am augmented in athero- 
sclerutic blood vessels in animals (25-n) and humans (28). In 
addition, inducible nitric oxide syitthase mRNA has been found in 
macrophages and vascular smooth muscle within human athero- 
sclerotic vessels (28). Thus, our present data are in agreement 
with the suggestion that the nitric oxide-generating capacity might 
be increased at spastic sites. Second, it has been reported that the 
production of et&helium-derived constricting factors such as 
endothelin ($2) and superoxide mdicak (29) also is augmented in 
atherosclerotic vessels. Coronary spasm usually results from non- 
specifk local hypermacdvity to VaSOCOllStriCtiOg stimuli that pro- 
duce only mild coustriction at nonapastic sites (7~3). Thus, it is 
possible that the blockade of nitric oxide synthesis by L-IWMA 
unmasked the effects of constricror stimuli so that the vasocon- 
stricting response to tNMMAwas apparent at the spastic site. In 
any case, our present ubsewutions suggest hat the basal reease 
0fnizriccoridemayWtbedeneasedatspasticsitesinpat;~~ 
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with variant angina. It should be noted that coronary constriction 
in response to the intracoronaty infusion of N”-nitro-L qinine 
methyl ester at the spastic site did not differ from the response at 
the control site in our swine model of coronary spasm (11). 
Previous studies also have shown that the basal tone (the 
percent dilation in response to isosorbide dinitrate) was aug- 
mented at spastic sites where coronaty artery spasm was provoked 
by the intracotonary administration of acetylcholine or ergono- 
vine in patients with variant angina (21-24). This also was 
observed in the present study. However, our present observations 
do not suggest hat a decreased release of nitric oxide contributed 
to the increased bara; tone at the spastic sites. 
Limltntions of the present study. The major limitation of this 
study is the fact that the spasm provocation test was performed 
after L-NMMA had ‘wren infused into the coronary artery. Thus, 
we must consider the possibiity that the responses to acetylcho- 
line might have been 1rSuenced by the presence of L-NMMA. 
However, all patients with variant angina and atypical chest pain 
underwent the same protocol, and coronary artery spasm was 
provoked by acetylcholine only in patients with variant angina 
We previously have reported, in our swine model of coronary 
spasm, that the intracoronaty infusion of N”-nitro-L-arginine 
methyl ester augmented the magnitude of serotonin-induced 
coustriction at nonspastic sites but did not al&t serotonin- 
induced spasm at spastic sites (11). These tindings suggest hat the 
inhibition of nitric oxide synthesis with L-arginine analogues may 
not inlluence the provocation of coronary artery spasm. Another 
limitation is that patients with normal coronary arteriograms were 
studied. Thus, we do not exclule the possibility that consttictor 
responses to L-NMMA at spastic sites might be altered in patients 
with advanced coronary atherosclerosis 
Condnsluns. Our present omervations suggest that the 
basal release of nitric oxide may not be decreased at spastic 
sites in patients with variant angina and normal coronary 
arteriograms. 
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